|
Groups
|
|---|
|
Parameters
|
FC
|
FT
|
R1
|
MC
|
MT
|
R2
|
|---|
|
Leukocyte (×103/mm3)
|
5.17 ± 0.853
|
7.18 ± 0.385
|
4.7 – 12.98 a
|
7.03 ± 0.677
|
7.70 ± 1.220
|
5.7 – 13.9 a
|
|
Erythrocytes (×106/mm3)
|
7.89 ± 0.395
|
8.60 ± 0.135
|
7.3 – 8.64 a
|
9.56 ± 0.249
|
9.66 ± 0.230
|
6.7 – 8.6a
|
|
Hemoglobin (g/dl)
|
13.43 ± 0.685
|
14.87 ± 0.225
|
13.2 – 15.1 a
|
15.59 ± 0.417
|
15.91 ± 0.309
|
12.8 – 15.9 a
|
|
Hematocrit (%)
|
42.93 ± 2.166
|
43.37 ± 0.569
|
39.1 – 48.5 a
|
48.43 ± 1.206
|
45.60 ± 0.649
|
39.1 – 48.7 a
|
|
VCM (fl)
|
54.40 ± 0.727
|
49.87 ± 0.201***
|
49.1 – 62.5 a
|
50.70 ± 0.439
|
47.21 ± 0.472***
|
50 – 59 a
|
|
HCM (pg)
|
17.00 ± 0.089
|
17.08 ± 0.065
|
16.6 – 18.9 a
|
16.31 ± 0.112
|
16.5 ± 0.104
|
17.0 – 19.5 a
|
|
CHCM (g/dl)
|
31.28 ± 0.433
|
34.27 ± 0.071***
|
29.9 – 34.9 a
|
32.17 ± 0.191
|
34.91 ± 0.265***
|
30.5 – 35.3 a
|
|
Platelets (×106/mm3)
|
1070 ± 74.760
|
1246 ± 59.830
|
757 – 1476 a
|
1198 ± 41.10
|
1141 ± 73.77
|
837 – 1455 a
|
|
Neutrophil (%)
|
48.40 ± 7.259
|
36.97 ± 2.070
|
5.4 – 37.5 a
|
45.84 ± 1.335
|
48.80 ± 3.384
|
17.1 – 47.9 a
|
|
Lymphocyte (%)
|
47.46 ± 5.432
|
57.73 ± 2.464
|
57.9 – 90.0 a
|
48.26 ± 1.716
|
46.09 ± 2.773
|
48.7 – 78.1 a
|
|
Monocyte (%)
|
2.857 ± 0.739
|
3.43 ± 0.814
|
0.6 – 7.9 a
|
3.47 ± 0.201
|
3.63 ± 0.432
|
1.0 – 6.5 a
|
|
Eosinophil (%)
|
1.60 ± 0.323
|
1.30 ± 0.206
|
0.2 – 4.5 a
|
0.16 ± 0.031
|
0.08 ± 0.016
|
0.3 – 4.0 a
|
-
FC (control female), FT (treated female), MC (control male), MT (treated male). N = 06. Data are expressed as mean ± S.D. * Indicate statistical difference between the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (reference female); R2 (reference male); a Melo (2012).
